We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Galderma Laboratories received an FDA warning letter that says the company overstated the efficacy of its Tri-Luma cream for the skin condition melasma in visual aids and minimized important risks.